menu
    • menu
    [{"orgOrder":0,"company":"Onxeo","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"$6.6 million","newsHeadline":"Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onxeo","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Onxeo \/ Acrotech Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Onxeo \/ Acrotech Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Belinostat

    Menu

    Belinostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onxeo

                            France arrow
                            Luxepack
                            Not Confirmed

                            Onxeo

                            France arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Acrotech Biopharma

                            Deal Size : $6.6 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

                            Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $6.6 million

                            April 06, 2020

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Acrotech Biopharma

                            Deal Size : $6.6 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth